Type 2 DiabetesCoronary Artery Disease (CAD)Atherosclerosis Cardiovascular Disease
Study summary
People with type 2 diabetes have a much higher risk of heart disease. One common problem is when the blood vessels that supply the heart become narrowed or blocked by fatty deposits, called plaque. This makes it harder for blood to reach the heart and can lead to serious problems such as chest pain, heart attacks, or even death.
This study will follow people with type 2 diabetes who have already had a special heart scan called a coronary CT angiography. This scan takes detailed pictures of the heart's blood vessels.
The goal is to understand how heart disease changes over time in people with type 2 diabetes, by looking at repeat scans and other health information. By learning more about how plaque builds up or gets worse, researchers hope to find better ways to identify which patients are most at risk for future heart problems.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age over 18 years
* Previous completion of CCTA scan for CAD assessment
* Diagnosed with Type 2 Diabetes and currently receiving glucose lowering treatment
* Sufficient image quality of the CCTA scan (at least 2/3 vessels of sufficient quality for assessment).
Exclusion Criteria:
* Inability to provide written informed consent
* Presence of an unstable condition
* Ingeligibility for CCTA acquisition due to severe renal dysfunction (eGFR ≤ 30 mL/min/1.73m²) or known hypersensitivity or contraindication to CT contrast agents
* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator
* inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study
* Baseline (routine care) CCTA performed \< 2 years or \> 5 years before inclusion
Primary outcome measure(s)
progression of total coronary plaque volume (mm3) — Between baseline (retrospective) and follow up CCTA (interval 2-5 years). The primary study parameter will be the progression of total coronary plaque volume (mm3). This will be calculated by subtracting the coronary plaque volume measured in the first CCTA from the total plaque volume measured in the follow-up CCTA. The plaque volume will be determined by dividing the total plaque volume by the total vesssel volume
Trial sites (2)
Facility
City
Region
Status
Amsterdam University Medical Centers
Amsterdam
Netherlands
Not Yet Recruiting
Cardiology Centers of the Netherlands
Amsterdam
Netherlands
Recruiting
More Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.